Literature DB >> 6204352

Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat.

E R Korpi, R J Wyatt.   

Abstract

Acute injection of rats with either haloperidol or reduced haloperidol (1 mg/kg, IP) greatly increased the striatal concentrations of the acidic dopamine metabolites, indicating enhanced turnover of dopamine. The effect of reduced haloperidol was almost as great as that of haloperidol. Reduced haloperidol, however, was much less efficient (about 400 times) than haloperidol in displacing [3H]spiperone binding to striatal membranes in vitro. In agreement with the above results, reduced haloperidol was found to be oxidized to haloperidol, so that 2 h after injection of reduced haloperidol the concentrations of haloperidol and reduced haloperidol were equal in the striatum. The apparent conversion of reduced haloperidol to haloperidol was much quicker in liver than in plasma or brain, and it is suggested that the conversion primarily occurs in the liver. Before drawing any definite conclusion about the possible central activity of reduced haloperidol, further studies with other animal species are needed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204352     DOI: 10.1007/bf00427418

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

Authors:  I Creese; S H Snyder
Journal:  Nature       Date:  1977-11-10       Impact factor: 49.962

2.  Rapid, concurrent analysis of dopamine, 5-hydroxytryptamine, their precursors and metabolites utilizing high performance liquid chromatography with electrochemical detection: analysis of brain tissue and cerebrospinal fluid.

Authors:  J A Nielsen; C A Johnston
Journal:  Life Sci       Date:  1982-12-20       Impact factor: 5.037

3.  Distribution excretion and metabolism of neuroleptics of the butyrophenone type. II. Distribution, excretion and metabolism of haloperidol in Sprague-Dawley rats.

Authors:  G A Braun; G I Poos; W Soudijn
Journal:  Eur J Pharmacol       Date:  1967-01       Impact factor: 4.432

4.  Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.

Authors:  E R Korpi; J E Kleinman; D T Costakos; M Linnoila; R J Wyatt
Journal:  Psychiatry Res       Date:  1984-03       Impact factor: 3.222

5.  Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection.

Authors:  M Scheinin; W H Chang; K L Kirk; M Linnoila
Journal:  Anal Biochem       Date:  1983-05       Impact factor: 3.365

6.  Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection.

Authors:  E R Korpi; B H Phelps; H Granger; W H Chang; M Linnoila; J L Meek; R J Wyatt
Journal:  Clin Chem       Date:  1983-04       Impact factor: 8.327

  6 in total
  20 in total

1.  Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.

Authors:  M W Kelly; P J Perry; W H Coryell; D D Miller; S V Arndt
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; John A Schetz
Journal:  Neurochem Int       Date:  2017-02-08       Impact factor: 3.921

Review 4.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.

Authors:  D W Eyles; H A Whiteford; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Synthesis of the enantiomers of reduced haloperidol.

Authors:  J C Jaen; B W Caprathe; S Priebe; L D Wise
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

9.  Biliary excretion of reduced haloperidol glucuronide.

Authors:  N D Eddington; D Young
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.

Authors:  W F Gattaz; A Emrich; S Behrens
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.